Reductil 15mg (Sibutramine) is used together with diet and exercise to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure.
Reductil 15mg (Sibutramine) is an drug for the treatment of central action obesity. The mechanism of action is due to selective inhibition of serotonin reuptake of norepinephrine and, to a lesser extent, of dopamine. This medication accelerates the onset and prolong satiety, which leads to a decrease in food consumption. It increases energy expenditure by stimulating thermogenesis mediated by activation of beta3-adrenergic receptors. Acts on both sides of the balance of energy and helps reduce body weight.
Dosage and administration
The recommended starting dose of Reductil (Reductil hydrochloride monohydrate) is 10 mg administered once daily with or without food. If there is inadequate weight loss, the dose may be titrated after four weeks to a total of 15 mg once daily. The 5 mg dose should be reserved for patients who do not tolerate the 10 mg dose. Blood pressure and heart rate changes should be taken into account when making decisions regarding dose titration.
Doses above 15 mg daily are not recommended. In most of the clinical trials, Reductil (Reductil hydrochloride monohydrate) was given in the morning.
Analysis of numerous variable s has indicated that approximately 60% of patients who lose at least 4 pounds in the first 4 weeks of treatment with a given dose of Reductil (Reductil hydrochloride monohydrate) in combination with a reduced-calorie diet lose at least 5% (placebo-subtracted) of their initial body weight by the end of 6 months to 1 year of treatment on that dose of Reductil (Reductil hydrochloride monohydrate). Conversely, approximately 80% of patients who do not lose at least 4 pounds in the first 4 weeks of treatment with a given dose of Reductil (Reductil hydrochloride monohydrate) do not lose at least 5% (placebo-subtracted) of their initial body weight by the end of 6 months to 1 year of treatment on that dose. If a patient has not lost at least 4 pounds in the first 4 weeks of treatment, the physician should consider reevaluation of therapy which may include increasing the dose or discontinuation of Reductil (Reductil hydrochloride monohydrate).
The safety and effectiveness of Reductil (Reductil hydrochloride monohydrate), as demonstrated in double-blind, placebo-controlled trials, have not been determined beyond 2 years at this time.
Reductil 15mg side effects, adverse reactions
Digestive system: frequently – anorexia, constipation, dry mouth, nausea, transient increases in liver enzymes.
CNS and peripheral nervous system: insomnia, headaches, dizziness, anxiety, paresthesia, increased sweating, change in taste, seizures; one patient with schizoaffective disorder, which presumably existed prior to initiating therapy with sibutramine after treatment developed acute psychosis.
Cardiovascular system: tachycardia, palpitations, increased blood pressure, vasodilation (flushing with a sensation of heat), exacerbation of hemorrhoids; in some cases – a more pronounced increase in blood pressure and heart rate acceleration.
Urinary system: in rare cases – acute interstitial nephritis, mesangiocapillary glomerulonephritis.
Blood coagulation system: thrombocytopenia, Henoch-Schonlein purpura.
Most often side effects occur early in therapy (the first 4 weeks), their severity and frequency of occurrence over time are weaken.
Reductil 15mg (Sibutramine) contraindications
Organic cause of obesity, well-known and established severe eating disorders (anorexia nervosa or bulimia nervosa), mental illness, Tourette syndrome, IBS, chronic heart failure in the stage of decompensation, congenital heart disease, occlusive peripheral artery disease, tachycardia, arrhythmias, cerebrovascular accident (including transient), uncontrolled hypertension (BP is more than 145/90 mm Hg), hyperthyroidism, severe renal dysfunction, severe hepatic dysfunction, benign prostatic hyperplasia with the formation of residual urine, pheochromocytoma, glaucoma, established pharmaceutical drug and alcohol abuse, pregnancy, lactation (breastfeeding), simultaneous taking or up to 2 weeks after discontinuation of MAO inhibitors or other drugs that have a dampening effect on the central nervous system (antidepressants, antipsychotics, tryptophan), or other medicines for weight loss, increased sensitivity to sibutramine.